Samyang Biopharm has launched its Lafullen dermal filler in Thailand, marking the Korean company's entry into one of Southeast Asia's fastest-growing aesthetic medicine markets.

The launch places Lafullen, Samyang's injectable hyaluronic acid-based soft tissue filler, in direct competition with established multinational brands that have long dominated the Thai aesthetics segment. Thailand has become a priority market for manufacturers of injectable aesthetics across the Asia-Pacific region, and Samyang's decision to commercialize Lafullen there signals the company's intent to build revenue outside its home base in South Korea.

Lafullen is part of a growing portfolio of Korean-developed hyaluronic acid fillers that have gained international regulatory clearances and market share over the past decade. Korean filler manufacturers have increasingly positioned their products on the combination of clinical performance and competitive pricing relative to legacy Western brands, a strategy that has resonated in price-sensitive but quality-conscious markets such as Thailand, Vietnam, Indonesia, and the broader Southeast Asian region.

Why Thailand

Thailand's aesthetic market has expanded rapidly, driven by a large domestic consumer base, a well-developed network of clinics in Bangkok and secondary cities, and a medical tourism industry that draws patients from across Asia, Europe, Australia, and the Middle East. Injectable treatments, including hyaluronic acid fillers and botulinum toxin products, rank among the most frequently performed minimally invasive procedures in Thai clinics.

That demand profile makes Thailand a logical commercial beachhead for a filler brand seeking regional scale. A successful Thai launch can serve as a reference market for neighboring countries, where distributors and clinicians often look to Thai adoption patterns when evaluating new products.

What Lafullen's entry means for clinicians

For Thai dermatologists, plastic surgeons, and aesthetic physicians, the arrival of Lafullen adds another hyaluronic acid option to a crowded field. Product selection in this segment typically turns on rheological properties, duration of effect, safety profile, and price — factors clinicians weigh against patient expectations and treatment area, whether mid-face volumization, nasolabial correction, or lip augmentation.

Samyang Biopharm, better known in Korea as a developer of biopharmaceuticals and drug-delivery technologies, has been diversifying its aesthetics business internationally. The Thai launch of Lafullen extends that strategy into a market where Korean aesthetic products already carry strong brand recognition among both practitioners and consumers.

Details regarding the specific Thai regulatory authorization, the filler's formulation characteristics, local distribution partners, and pricing were not disclosed in the announcement.

Competitive context

The Thai filler market has historically been led by global manufacturers with long-established product lines and extensive clinician training programs. New entrants must compete not only on product attributes but also on education, injection training support, and marketing investment — the infrastructure that drives adoption in a market where physician recommendation carries substantial weight in consumer choice.

Korean manufacturers have closed that gap across Asia in recent years, leveraging the regional influence of Korean beauty and medical aesthetics culture. Thai consumers' familiarity with Korean aesthetic brands may lower the adoption barrier for Lafullen relative to fillers from manufacturers without comparable regional visibility.

Outlook

The Thailand launch is a commercial milestone for Samyang's aesthetics division, but the durability of Lafullen's position will depend on real-world clinician experience, competitive pricing against incumbent brands, and the company's ability to build practitioner support programs at scale. If the Thai market responds, Samyang is positioned to extend Lafullen's footprint across Southeast Asia, where demand for hyaluronic acid injectables continues to grow.

Derm Field will monitor post-launch developments, including any disclosed sales figures, regulatory clearances in additional markets, and clinical data on Lafullen's performance, as Samyang Biopharm advances its international aesthetics strategy.